Please login to the form below

Not currently logged in
Email:
Password:

ECTRIMS 2021

This page shows the latest ECTRIMS 2021 news and features for those working in and with pharma, biotech and healthcare.

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis. ... Our presentations at ECTRIMS 2021 bolster the growing body of evidence underscoring the

Latest news

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...